1. Home
  2. TECX vs PRTC Comparison

TECX vs PRTC Comparison

Compare TECX & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TECX
  • PRTC
  • Stock Information
  • Founded
  • TECX 2019
  • PRTC 2015
  • Country
  • TECX United States
  • PRTC United States
  • Employees
  • TECX N/A
  • PRTC N/A
  • Industry
  • TECX
  • PRTC Biotechnology: Pharmaceutical Preparations
  • Sector
  • TECX
  • PRTC Health Care
  • Exchange
  • TECX Nasdaq
  • PRTC Nasdaq
  • Market Cap
  • TECX 387.1M
  • PRTC 435.0M
  • IPO Year
  • TECX 2018
  • PRTC N/A
  • Fundamental
  • Price
  • TECX $19.02
  • PRTC $18.18
  • Analyst Decision
  • TECX Buy
  • PRTC
  • Analyst Count
  • TECX 6
  • PRTC 0
  • Target Price
  • TECX $79.17
  • PRTC N/A
  • AVG Volume (30 Days)
  • TECX 515.4K
  • PRTC 2.3K
  • Earning Date
  • TECX 11-06-2025
  • PRTC 08-28-2025
  • Dividend Yield
  • TECX N/A
  • PRTC N/A
  • EPS Growth
  • TECX N/A
  • PRTC N/A
  • EPS
  • TECX N/A
  • PRTC 0.20
  • Revenue
  • TECX N/A
  • PRTC $6,391,000.00
  • Revenue This Year
  • TECX N/A
  • PRTC N/A
  • Revenue Next Year
  • TECX N/A
  • PRTC N/A
  • P/E Ratio
  • TECX N/A
  • PRTC $8.46
  • Revenue Growth
  • TECX N/A
  • PRTC 1265.60
  • 52 Week Low
  • TECX $13.70
  • PRTC $13.30
  • 52 Week High
  • TECX $61.07
  • PRTC $24.99
  • Technical
  • Relative Strength Index (RSI)
  • TECX 61.68
  • PRTC 54.80
  • Support Level
  • TECX $16.98
  • PRTC $17.26
  • Resistance Level
  • TECX $18.77
  • PRTC $18.17
  • Average True Range (ATR)
  • TECX 1.30
  • PRTC 0.26
  • MACD
  • TECX 0.54
  • PRTC -0.04
  • Stochastic Oscillator
  • TECX 96.12
  • PRTC 47.42

About TECX Tectonic Therapeutic Inc. Common Stock

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

About PRTC PureTech Health plc

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

Share on Social Networks: